Business Context and Reporting Period
This Form 8-K Current Report was filed by Calidi Biotherapeutics, Inc. (CLDI) on April 8, 2025. The filing discloses a material corporate event under Item 7.01 (Regulation FD Disclosure) regarding the appointment of new executive leadership.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the new executive compensation agreement:
- Consulting Fees: $20,833.33 per month for the new Chief Medical Officer.
- Contract Term: One year (April 8, 2025, to April 8, 2026).
Material Changes
The primary material change reported is the appointment of Guy Travis Clifton, M.D., as Chief Medical Officer, Consultant, and Advisor. Dr. Clifton brings over 17 years of experience in drug development, clinical trials, and cancer immunotherapy, including prior roles as CMO and co-founder at Parthenon Therapeutics/Incendia Therapeutics.
Outlook, Risks, and Management Commentary
Management commentary is limited to the strategic value of Dr. Clifton's expertise in medical and scientific areas. The filing includes standard disclaimers stating that the information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act. No specific financial guidance, risk factors, or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the press release dated April 10, 2025, for additional details on Dr. Clifton's appointment.
- Review the amended and restated consulting agreement (Exhibit 99.1) for full terms and conditions.
- Check subsequent filings (10-Q or 10-K) for the impact of this new compensation on the company's operating expenses.
- Confirm the company's current cash position to assess the ability to fund the new executive role alongside ongoing clinical trials.